Selank

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW 751.90 g/mol, CAS 129954-34-3) derived from the immunomodulator tuftsin. It is investigated for anxiolytic and nootropic activity via GABAergic, serotonergic and BDNF pathways [11][2]. South African researchers seeking to buy Selank peptide in 2026 work in a specific context: no SAHPRA schedule listing, no indexed local university publications citing the compound, and no post-2023 human RCTs in PubMed [6][1][13].

This guide covers the mechanistic basis of Selank's anxiolytic and nootropic effects, the practical procurement pathway through Body Pharm Selank 10 via JCSG.org, and the regulatory position for preclinical labs in Cape Town, Johannesburg, Stellenbosch and Pretoria [14][9].

Key Takeaways

• Selank is a seven-residue peptide (TKPRPGP, 751.90 g/mol) engineered to stabilise tuftsin against plasma degradation
• The evidence base is concentrated in Russian-language rodent studies; no peer-reviewed human RCT has been published since 2023
• Selank modulates GABA and BDNF expression indirectly, without binding benzodiazepine sites, producing anxiolytic-like behaviour without sedation in animal models
• In South Africa, Selank is unscheduled under SAHPRA and available for research use only through retailers such as JCSG.org
• The closest mechanistic comparator is Semax, which shares the Pro-Gly-Pro stabilising tail but derives from ACTH(4-7) rather than tuftsin

What Is Selank? Definition and Sequence

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Its molecular formula is C33H57N11O9 and molecular weight 751.90 g/mol. The Institute of Molecular Genetics of the Russian Academy of Sciences synthesised it as a stabilised analogue of the endogenous immunopeptide tuftsin [6][2]. It carries CAS number 129954-34-3 and rounds to 752 Da to three significant figures [6][2].

The N-terminal four residues (Thr-Lys-Pro-Arg) reproduce tuftsin itself, a tetrapeptide cleaved from the CH2 domain of the IgG heavy chain, with phagocyte-stimulating and immunomodulatory activity [2]. Tuftsin alone is rapidly hydrolysed in plasma by leucine aminopeptidase and tuftsin-specific peptidases. That rapid degradation is the practical problem the Russian Academy group set out to solve.

The Pro-Gly-Pro tail

Appending the tripeptide Pro-Gly-Pro to the C-terminus of tuftsin yields Selank. This extension substantially increases its half-life against exopeptidase degradation. The proline residues sterically hinder peptidase cleavage at the C-terminal end, which is why this extension was selected over alternatives. That stability is what makes intranasal dosing pharmacologically viable in the rodent and human protocols cited in current dosing literature [1][2].

For researchers cross-comparing nootropic heptapeptides, the closest structural and mechanistic neighbour is Semax research peptide, an ACTH(4-10) analogue with overlapping BDNF activity. Both appear in the broader JCSG.org peptide catalogue of regulatory peptides.

Selank vs Tuftsin: Structural Differences

Selank was engineered rather than dosed as tuftsin directly. Tuftsin (Thr-Lys-Pro-Arg) is hydrolysed in plasma within minutes by leucine aminopeptidase and tuftsin-specific endocarboxypeptidase. The Pro-Gly-Pro C-terminal extension in Selank sterically blocks exopeptidase access, producing a peptide stable enough for intranasal protocols [1][2]. The four-residue parent and the seven-residue analogue share the same N-terminal pharmacophore but behave very differently in serum.

The classic tuftsin half-life figure traces to Najjar's 1987 plasma stability work, which puts intact tuftsin in the order of minutes before cleavage at the Lys-Pro bond (pre-2023, potentially stale). Selank's stability is inferred from the Semenova et al. (2010) gene-expression timecourses, which require an intact heptapeptide reaching CNS targets over a behaviourally relevant window [6]. The Pro-Gly-Pro motif is a known β-turn-inducing sequence in structural peptide studies, one reason it was selected as the stabilising tail rather than, say, a poly-alanine extension.

Property	Tuftsin	Selank
Residues	4 (TKPR)	7 (TKPRPGP)
Molecular weight	500.6 g/mol	751.90 g/mol [11]
Plasma half-life	~minutes (Najjar 1987, stale)	Extended; viable for intranasal dosing [1]
Primary activity	Phagocyte stimulation, immunomodulation	Anxiolytic, nootropic, GABA/BDNF modulation [6][2]

For researchers benchmarking Selank against another tail-stabilised neuropeptide analogue, Semax follows the same engineering logic applied to ACTH(4-10). Both appear in the JCSG.org peptide catalogue.

GABAergic Mechanism: What the Research Shows

Selank does not bind GABA-A receptors directly. Instead, it modulates GABAergic tone indirectly via enkephalinase inhibition and downstream gene-expression changes in neurotransmission pathways. Semenova et al. (2010) showed that intranasal Selank in rodents alters expression of genes coupled to GABAergic signalling, this is the mechanistic basis cited in every 2024-2026 secondary review I have located [4][5]. No 2024-2026 work materially updates this model with receptor-binding or subunit-resolved electrophysiology [5].

The proposed pathway runs through stabilisation of endogenous enkephalins. By inhibiting enkephalin-degrading peptidases, Selank prolongs the action of peptides that feed into limbic GABAergic circuits. This produces an anxiolytic-like phenotype without the direct chloride-channel potentiation that defines benzodiazepine action [5]. Consistent with this, the rodent studies report no sedation, ataxia, or muscle relaxation at anxiolytic doses, responses you would expect if a benzodiazepine-like allosteric site were engaged [5].

Behavioural Evidence in Rodent Models

Anxiolytic-like behaviour has been demonstrated in elevated plus-maze and open-field paradigms in Wistar rats, with increased open-arm time and unchanged locomotor counts compared to controls as the typical readouts. The Zozulya et al. (2001) Bulletin of Experimental Biology and Medicine work is frequently cited in the secondary literature for this behavioural profile (pre-2023, flagged as potentially stale; the original Russian-language primary data have not been re-run in published Western replications) [5][7]. Semenova's 2010 gene-expression timecourses align temporally with the behavioural window, which is the strongest mechanistic-behavioural bridge currently in print [4].

Two caveats apply for the South African preclinical reader. First, no peer-reviewed human RCT of Selank has been published in 2023-2026, so all GABAergic claims rest on rodent and Russian-language clinical observational data [5][7]. Second, the closest tail-stabilised comparator with overlapping BDNF activity is Semax. Benchmarking the two in the same behavioural battery remains an open opportunity within the JCSG.org peptide catalogue.

BDNF Expression and Neuroprotective Signals

Selank administration is associated with increased BDNF mRNA expression in the hippocampus of rodents. The most-cited primary data come from Inozemtseva et al. (2008, Doklady Biological Sciences; pre-2023, flagged as potentially stale) and from the gene-expression timecourses reported by Semenova and colleagues [1]. The 2026 secondary literature continues to summarise Selank as modulating GABA, serotonin and BDNF pathways without adding new receptor-binding or protein-quantification data beyond the pre-2020 Russian work [2][3].

mRNA Versus Protein-Level Endpoints

This distinction matters for any South African preclinical group designing a Selank study. The published evidence base is dominated by transcript-level readouts (qPCR, microarray) rather than ELISA- or Western-quantified mature BDNF protein in hippocampal lysate. mRNA upregulation does not automatically translate into proportional protein output. The proBDNF-to-mature-BDNF processing step determines whether the signal is pro-survival (TrkB) or pro-apoptotic (p75NTR), and that processing step is not resolved in the existing Selank literature [1][2]. Any local replication should pair transcript work with protein quantification and, ideally, TrkB phosphorylation readouts.

Why BDNF Is a Live 2025-2026 Endpoint

BDNF remains a central node in synaptic plasticity, adult hippocampal neurogenesis models, and stress-resilience paradigms, which is why nootropic and anxiolytic peptide programmes continue to use it as a primary mechanistic endpoint. The closest tail-stabilised comparator with overlapping BDNF activity is the Semax research peptide. Head-to-head BDNF timecourses between the two heptapeptide analogues within the JCSG.org peptide catalogue would fill a genuine gap in the comparative literature.

No peer-reviewed human data on Selank-induced BDNF changes has been published as of the 2026 literature search. The existing 2024-2026 reviews explicitly note that Western replication of the Russian mechanistic work remains sparse and that no FDA- or EMA-registered trials exist [2][3]. Hippocampal BDNF claims should be reported as rodent-restricted until protein-level human data appear.

Immune Modulation: Tuftsin Heritage

Selank inherits its immunomodulatory profile from tuftsin, the endogenous tetrapeptide Thr-Lys-Pro-Arg (TKPR) that forms the N-terminal core of the TKPRPGP sequence and drives macrophage and natural killer cell activation in classical immunology assays [3]. The Pro-Gly-Pro tail extends plasma half-life relative to free tuftsin, which is rapidly cleaved by leucyl aminopeptidase, while preserving the receptor-recognition motif responsible for phagocyte stimulation.

Cytokine Readouts in Rodent Stress Models

Rodent work on Selank has reported shifts in IL-6 and TNF-α profiles under restraint and chronic mild stress paradigms, consistent with a dampening of stress-induced pro-inflammatory tone rather than blanket immunosuppression [3]. The cytokine dataset most often cited in current reviews predates 2023 and has not been re-run with contemporary multiplex panels (Luminex, MSD). Subunit-level resolution of Th1/Th2/Th17 balance remains unresolved in the 2024-2026 literature [3][6].

Immune-Neuroendocrine Crosstalk

The tuftsin lineage is what separates Selank from a purely nootropic comparator like the Semax research peptide. Semax derives from ACTH(4-10) and lacks a documented macrophage-activating motif. For South African groups planning comparative work across the JCSG.org peptide catalogue, pairing Selank and Semax arms with matched serum cytokine and hippocampal BDNF readouts would directly test whether the immune signal is a confound or a contributor to the anxiolytic phenotype.

All immune-modulation claims for Selank rest on in-vivo rodent and in-vitro assay data. No peer-reviewed human immunology trial has been published as of the 2026 search. Cytokine effects should be reported as preclinical only [3][6].

Body Pharm Selank 10, Product Specification

Body Pharm Selank 10 is a 10 mg lyophilised heptapeptide vial supplied for research use only. The same Body Pharm line manufactures CJC-1295 and GHK-Cu SKUs that circulate through South African research-peptide retailers including JCSG.org [2][3]. The active compound is the TKPRPGP sequence, molecular formula C33H57N11O9, molecular weight 751.90 g/mol, CAS 129954-34-3 [10][11].

Storage and Reconstitution

Store lyophilised Selank at −20 °C, desiccated, and shielded from light to preserve peptide integrity over a working timeframe of months rather than weeks. Once reconstituted with bacteriostatic water or sterile 0.9% saline, the resulting solution is typically aliquoted and stored at 2-8 °C for short-term use. Longer holds should go back to −20 °C in single-use volumes to avoid freeze-thaw degradation. Reconstitution volume is a lab-level decision driven by the planned assay concentration, not a therapeutic dose.

Purity Verification

Research-grade neuropeptides are commonly specified at ≥98% HPLC. Body Pharm marketing for the broader line references purity at that order of magnitude. No Selank-specific certificate of analysis with a line-item HPLC percentage and batch number is openly indexed as of 2026 [2]. Request the batch-matched CoA from the vendor at purchase rather than relying on catalogue copy.

Groups running comparative neuropeptide arms can cross-reference the Semax research peptide entry and the broader JCSG.org peptide catalogue for parallel product specifications.

Buying Selank in South Africa: What Researchers Need to Know in 2026

You can procure Selank in South Africa as a research-use-only chemical. As of 2026, it does not appear on any SAHPRA schedule under the Medicines and Related Substances Act 101 of 1965 and is not listed on the SAHPRA medicines or biologicals register [3]. That status places it in the general unregistered-medicine / research-compound category rather than under a specific schedule. Verify the current SAHPRA position at the date of order, since scheduling notices can be gazetted at short notice [3].

Research-Use Supply Versus Clinical Use

Selank has no FDA, EMA, or SAHPRA marketing authorisation. No peer-reviewed human RCT has been published between 2023 and 2026 [2][13]. Domestic supply through research-peptide retailers such as JCSG.org is for in-vitro and preclinical in-vivo work only, not for human administration, compounding, or resale as a finished medicine. Any vendor copy that frames Selank as a treatment for anxiety or cognitive complaints in humans is operating outside the registered-medicines framework.

Ethics Clearance for In-Vivo Work

Institutional researchers running animal or human-tissue protocols with Selank should secure clearance from their institutional Research Ethics Committee. Where applicable, register the protocol with the National Health Research Ethics Council (NHREC) before ordering material. Animal work additionally requires AEC approval at the host institution. Procurement records, batch-matched CoAs, and storage logs should be retained against the ethics file.

Pricing and Local Availability

Body Pharm Selank 10 is distributed in South Africa via research-peptide retailers including JCSG.org. Live ZAR pricing is on the product listing page rather than quoted here, as catalogue prices shift across 2026 [5][6]. Researchers comparing nootropic neuropeptide arms should consult the Semax research peptide entry as the closest mechanistic comparator. The broader JCSG.org peptide catalogue lists adjacent SKUs.

Selank vs Semax: Choosing the Right Research Peptide

Selank and Semax are both Russian-developed regulatory peptides with overlapping nootropic interest but distinct parent lineages and primary mechanisms. Selank derives from tuftsin (immune-active tetrapeptide) and is studied chiefly for GABAergic modulation and anxiolytic-like endpoints. Semax derives from ACTH(4-7) and is studied for BDNF/NGF upregulation and cognitive/neuroprotective endpoints [4][5].

Parameter	Selank	Semax
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)	Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Parent peptide	Tuftsin (TKPR) + Pro-Gly-Pro tail	ACTH(4-7) + Pro-Gly-Pro tail
Molecular weight	751.90 g/mol [12][13]	~813 g/mol
Primary mechanism	GABAergic modulation; tuftsin-linked immune signalling [14]	BDNF/NGF upregulation; melanocortin signalling
Key preclinical endpoints	Anxiolytic-like behaviour in rodents; enkephalin stabilisation [4]	Cognitive enhancement, ischaemic neuroprotection models
Stability profile	Pro-Gly-Pro C-terminus confers resistance to peptidase cleavage; intranasal route standard [4]	Same Pro-Gly-Pro stabilisation; intranasal route standard

For researchers running parallel anxiolytic-versus-nootropic arms, the practical decision rests on endpoint. GABA/serotonin readouts and open-field anxiety models favour Selank. Spatial memory, BDNF assays, and ischaemia-reperfusion paradigms favour Semax. The Semax research peptide page covers the comparator in equivalent depth, and the full JCSG.org peptide catalogue lists adjacent neuropeptide SKUs for combined-arm protocols. Mechanistic comparisons across the regulatory-peptide family in Myasoedov and colleagues (2013, pre-2023) remain the most cited cross-compound reference.

Research Literature: Key Studies and Evidence Quality (2026 Update)

The Selank evidence base, as of a 2026 literature search, remains concentrated in Russian-language and Russian-affiliated publications spanning roughly 2000 to 2023, dominated by rodent behavioural and gene-expression work. A small number of open-label human pilot studies exist, but no large-scale double-blind randomised controlled trial has been published in any indexed journal [4]. Practitioner and mechanism overviews dated 2026 explicitly note the absence of FDA/EMA-registered trials and describe Western replication as sparse [2].

The mechanistic backbone most often cited is Semenova and colleagues (2010, pre-2023) on Selank-induced changes in GABAergic neurotransmission gene expression, the reference point for allosteric GABA-modulation framing in 2024-2026 reviews [14][2]. Tuftsin-lineage immune and cytokine work from Zozulya and Kozlovskaya groups, together with BDNF/serotonin pathway summaries, fill out the mechanistic picture but have not been independently reproduced at scale outside the original Russian collaborative network [1][2]. Publication is concentrated in Bulletin of Experimental Biology and Medicine and Doklady Biological Sciences, which constrains cross-database visibility.

Recommended PubMed search string

For researchers building a current reference set, I run:

Selank[Title/Abstract] AND (GABA OR BDNF OR tuftsin OR anxiolytic)

Filtering by date range 2010:2026 and screening author affiliations (Semenova MM, Zozulya AA, Kozlovskaya MM, Myasoedov NF) captures the bulk of the mechanistic corpus. A parallel search swapping "Selank" for "Semax" surfaces the closest comparator literature. The Semax research peptide page summarises that overlap, and the broader JCSG.org peptide catalogue lists adjacent neuropeptides for combined-protocol design.

The honest gap to flag in any methods section: internally consistent Russian data, minimal Western replication, zero indexed RCTs 2023-2026 [4].

Frequently Asked Questions About Selank